Latest Commercialisation News

Omega Oil and Gas has reported robust oil and gas flows from its Canyon-1H well in Queensland’s Bowen Basin, confirming commercial potential and securing $7 million in fresh capital alongside a strategic board appointment.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

Lithium Plus Minerals Limited (ASX: LPM) reported significant progress on its Lei Lithium Development with advancing environmental approvals and infrastructure design, while its Wingate Project reveals promising large-scale gold potential. The company maintains a solid cash position of AUD 3.6 million as it prepares for upcoming exploration campaigns.

Cadoux Limited has made significant progress in its High Purity Alumina and Minhub rare earth projects during Q1 2025, advancing engineering studies, securing key contracts, and strengthening ESG initiatives while preparing for commercialisation.

Renegade Exploration reports significant discoveries of critical defence metals germanium and gallium at its Yukon Andrew Deposit, alongside promising gold-silver prospects, while progressing copper and cobalt projects in Queensland amid a tight cash position.

Zenith Minerals reported a pivotal quarter advancing exploration at its Dulcie Far North and Red Mountain gold projects, while agreeing to divest its Turkish Kavaklitepe interest, sharpening its focus on domestic assets.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

Dotz Nano has successfully demonstrated its DotzEarth direct air capture technology at lab scale and secured a A$4 million investment to advance to real-world pilot testing, signaling growing momentum in its carbon capture ambitions.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Nanollose Limited has achieved a significant milestone by blending its Nullarbor-20™ sustainable fibre with Australian merino wool to produce pilot blankets, while also completing a $672,000 placement to fund ongoing commercialisation efforts.